Sonoma Pharmaceuticals, Inc. (SNOA)
1.32
-0.01
(-0.75%)
USD |
NASDAQ |
Sep 09, 16:00
1.32
0.00 (0.00%)
After-Hours: 19:08
Sonoma Pharmaceuticals Enterprise Value : 1.766M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 1.766M |
| September 04, 2026 | 1.742M |
| September 03, 2026 | 1.718M |
| September 02, 2026 | 1.575M |
| September 01, 2026 | 1.575M |
| August 31, 2026 | 1.575M |
| August 28, 2026 | 1.670M |
| August 27, 2026 | 1.766M |
| August 26, 2026 | 2.005M |
| August 25, 2026 | 1.862M |
| August 24, 2026 | 1.814M |
| August 21, 2026 | 1.814M |
| August 20, 2026 | 1.814M |
| August 19, 2026 | 1.910M |
| August 18, 2026 | 1.622M |
| August 17, 2026 | 1.718M |
| August 14, 2026 | 1.622M |
| August 13, 2026 | 1.814M |
| August 12, 2026 | 1.958M |
| August 11, 2026 | 1.958M |
| August 10, 2026 | 1.575M |
| August 07, 2026 | 2.293M |
| August 06, 2026 | 1.383M |
| August 05, 2026 | 0.809M |
| August 04, 2026 | 1.144M |
| Date | Value |
|---|---|
| August 03, 2026 | 0.7611M |
| July 31, 2026 | 0.6654M |
| July 30, 2026 | 0.809M |
| July 29, 2026 | 0.6654M |
| July 28, 2026 | 0.8568M |
| July 27, 2026 | 0.9047M |
| July 24, 2026 | 0.8568M |
| July 23, 2026 | 0.9525M |
| July 22, 2026 | 0.9525M |
| July 21, 2026 | 1.12M |
| July 20, 2026 | 1.000M |
| July 17, 2026 | 1.192M |
| July 16, 2026 | 1.240M |
| July 15, 2026 | 1.240M |
| July 14, 2026 | 1.288M |
| July 13, 2026 | 1.431M |
| July 10, 2026 | 1.431M |
| July 09, 2026 | 1.431M |
| July 08, 2026 | 1.335M |
| July 07, 2026 | 1.288M |
| July 06, 2026 | 1.383M |
| July 02, 2026 | 1.192M |
| July 01, 2026 | 1.192M |
| June 30, 2026 | 1.288M |
| June 29, 2026 | 0.6559M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.848B |
| Corcept Therapeutics, Inc. | 12.00B |
| Veru, Inc. | 20.88M |
| Johnson & Johnson | 676.38B |
| Eli Lilly & Co. | 1.104T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.33M |
| Revenue (Quarterly) | 6.406M |
| Total Expenses (Quarterly) | 6.736M |
| EPS Diluted (Quarterly) | -0.0858 |
| Gross Profit Margin (Quarterly) | 40.23% |
| Profit Margin (Quarterly) | -5.15% |
| Earnings Yield | -92.24% |
| Normalized Earnings Yield | -92.24 |